Huang, H., Gao, Y., Li, X., Zhang, X., Wang, X., Bai, B., Feng, R., FU, M. (2025). Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7006